Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy.

Global journal of obesity, diabetes and metabolic syndrome Pub Date : 2018-01-01 DOI:10.17352/2455-8583.000032

Michael Ashamalla, Irini Youssef, Mena Yacoub, Apoorva Jayarangaiah, Nikita Gupta, Justina Ray, Sadat Iqbal, Regina Miller, Joie Singh, Samy I McFarlane

{"title":"Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy.","authors":"Michael Ashamalla, Irini Youssef, Mena Yacoub, Apoorva Jayarangaiah, Nikita Gupta, Justina Ray, Sadat Iqbal, Regina Miller, Joie Singh, Samy I McFarlane","doi":"10.17352/2455-8583.000032","DOIUrl":null,"url":null,"abstract":"<p><p>The association between Diabetes and cancer has been known for decades with obesity and insulin resistance being postulated as the main underlying risk factors for both disorders. With rise of the epidemic of obesity in the USA and around the globe, there has been a rise in diabetes that is currently reaching epidemic proportions. Diabetes is known to be associated with increased risk of several types of malignancy including breast, cervical, pancreatic and colon cancer. In this review, we discuss the epidemic of obesity and its consequential epidemic of diabetes highlighting the pathophysiologic mechanisms of increased cancer in the diabetic population. We will then discuss the role of insulin therapy as well as, other antidiabetic medications, particularly metformin that has been to be associated with lower risk as well as better survival with GI malignancies based on several studies including a study that was recently published by our group.</p>","PeriodicalId":73168,"journal":{"name":"Global journal of obesity, diabetes and metabolic syndrome","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global journal of obesity, diabetes and metabolic syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/2455-8583.000032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

The association between Diabetes and cancer has been known for decades with obesity and insulin resistance being postulated as the main underlying risk factors for both disorders. With rise of the epidemic of obesity in the USA and around the globe, there has been a rise in diabetes that is currently reaching epidemic proportions. Diabetes is known to be associated with increased risk of several types of malignancy including breast, cervical, pancreatic and colon cancer. In this review, we discuss the epidemic of obesity and its consequential epidemic of diabetes highlighting the pathophysiologic mechanisms of increased cancer in the diabetic population. We will then discuss the role of insulin therapy as well as, other antidiabetic medications, particularly metformin that has been to be associated with lower risk as well as better survival with GI malignancies based on several studies including a study that was recently published by our group.

查看原文本刊更多论文

肥胖、糖尿病和胃肠道恶性肿瘤:二甲双胍和其他抗糖尿病治疗的作用。

糖尿病和癌症之间的联系几十年来一直为人所知，肥胖和胰岛素抵抗被认为是这两种疾病的主要潜在危险因素。随着肥胖在美国和全球范围内的流行，糖尿病的发病率也在上升，目前已达到流行病的程度。众所周知，糖尿病与几种恶性肿瘤的风险增加有关，包括乳腺癌、宫颈癌、胰腺癌和结肠癌。在这篇综述中，我们讨论了肥胖的流行及其相应的糖尿病流行，强调了糖尿病人群中癌症增加的病理生理机制。然后我们将讨论胰岛素治疗的作用，以及其他抗糖尿病药物，特别是二甲双胍，根据几项研究，包括我们小组最近发表的一项研究，二甲双胍与胃肠道恶性肿瘤的低风险和更好的生存率有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global journal of obesity, diabetes and metabolic syndrome

自引率

0.00%

发文量